Growth Hormone Secretagogues & GHRH Analogs
Ipamorelin
Last reviewed: 2026-11-19
Evidence status & limitations
A randomized postoperative bowel-function study did not meet its primary efficacy endpoint; hormone release does not establish other clinical benefits.
Regulatory status
No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
FDA notes immune and impurity concerns; rare-event and long-term safety remain uncertain.
Key sources
Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.
Related compounds
- CJC-1295
Same scientific class · A 29-amino-acid chain. · Early human trials
- Examorelin
Same target family · A 6-amino-acid chain. · Early human trials
- Modified GRF (1–29)
Same scientific class · A 29-amino-acid chain. · Cell/lab studies only
- Pralmorelin
Same target family · A 6-amino-acid chain. · Early human trials
- Sermorelin
Same scientific class · A 29-amino-acid chain. · Late-stage human trials